Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
Crossover Experiments01:16

Crossover Experiments

Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative genomics and phenotypes of Listeria monocytogenes isolated from enoki mushrooms in South Korea and China.

Food microbiology·2026
Same author

Atypical short tandem repeat allelic patterns in a sexual assault case involving hematopoietic stem cell transplantation.

Journal of forensic sciences·2026
Same author

Molecular concentration field design using closed-form steady-state solutions.

Soft matter·2026
Same author

Molecular dynamics simulation of atomic layer etching for sidewall damage recovery in GaN-based structures.

Scientific reports·2026
Same author

Effects of <i>Haematococcus lacustris</i>-Supplemented Diets on the Development of Body Color and Health of Giant Freshwater Prawn (<i>Macrobrachium rosenbergii</i>).

Development & reproduction·2026
Same author

[Estimating and evaluating usual total fat and fatty acid intake in the Korean population using data from the 2019-2021 Korea National Health and Nutrition Examination Surveys: a cross-sectional study].

Korean journal of community nutrition·2025

Related Experiment Video

Updated: May 8, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Group sequential designs for developing and testing biomarker-guided personalized therapies in comparative

Tze Leung Lai1, Olivia Yueh-Wen Liao, Dong Woo Kim

  • 1Department of Statistics, Stanford University, Stanford, CA, USA.

Contemporary Clinical Trials
|September 3, 2013
PubMed
Summary

Biomarker-guided personalized therapies promise better patient care but pose clinical trial design challenges. New group sequential designs are introduced for developing and testing personalized treatment strategies.

Keywords:
Adaptive randomizationBiomarker classifiersGeneralized likelihood ratio statisticsGroup sequential designMultiple testingTargeted therapies

More Related Videos

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
09:00

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

Related Experiment Videos

Last Updated: May 8, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
09:00

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

Area of Science:

  • Clinical trial design
  • Biomarker-guided therapies
  • Personalized medicine

Background:

  • Biomarker-guided personalized therapies offer significant potential for improving drug development and patient outcomes.
  • Designing and validating clinical trials for these advanced therapies presents substantial challenges.
  • Existing trial approaches for new drug development and comparative effectiveness trials with approved treatments are reviewed.

Purpose of the Study:

  • To address the challenges in clinical trial design for biomarker-guided personalized therapies.
  • To review current methodologies for clinical trials in drug development and comparative effectiveness.
  • To introduce novel group sequential designs for developing and validating personalized treatment strategies.

Main Methods:

  • Review of existing clinical trial designs for new drug development.
  • Detailed review of comparative effectiveness trial designs involving approved treatments.
  • Introduction of new group sequential designs tailored for personalized treatment strategies.

Main Results:

  • Identification of key challenges in current clinical trial designs for personalized medicine.
  • Comprehensive overview of established trial methodologies.
  • Development of innovative group sequential designs for personalized treatment strategy evaluation.

Conclusions:

  • Effective clinical trial design is crucial for realizing the potential of personalized medicine.
  • Novel group sequential designs offer a promising approach for developing and validating personalized treatment strategies.
  • Further research and application of these designs can accelerate the integration of personalized therapies into patient care.